It has been previously reported that the expression of hBD1 is deficient or reduced in many renal cell carcinomas, prostate cancers [56], basal cell carcinomas [57] and oral squamous cell carcinomas (OSCC) [58]. Here, DEFB1 is linked to renal cell carcinoma.